COLCHICORT Trial The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors. https://t.co/CC2yVRXbD5 https://t.co/ebLa3FUbGR

• COLCHICORT Trial | RheumNow

A new player in AIRD ThA age associated T helper cells Displaying both Cytotoxic & APC functions Correlation with disease activity in RA and SLE More research is needed to better characterize function but could be a promising therapeutic target @RheumNow #APLAR25 https://t.co/4SnY65tXpJ

• https://x.com/AurelieRheumo/status/1964216189477093887/photo/1

What to give next? Bone sequencing therapy provides a novel perspective in #osteoporosis treatment. Several sequential approaches exist. Better treatment plan = better patient outcomes #APLAR25 @RheumNow @rheumarhyme https://t.co/XvwnT9ZCU2

• https://x.com/RHEUMarampa/status/1964173064020906074/photo/1
• https://x.com/RHEUMarampa/status/1964173064020906074/photo/1
• https://x.com/RHEUMarampa/status/1964173064020906074/photo/1

This slide reflects the rheumatologist’s goals for treating #lupus Prof. Mosca also highlights the fact that achieving targets is as important as maintaining these treatment targets. @RheumNow #APLAR25 https://t.co/u8fw3fThXI

• https://x.com/RHEUMarampa/status/1964141957275644392/photo/1

Prof. Eric Morand on the SLE T2T approach. Ultimate goal is remission but we know that not all patients achieve this state. Thru the T2T approach, low dse activity (LLDAS) is an acceptable target & a protective alternative goal @RheumNow #APLAR25 #Lupus https://t.co/vz7E5prps0

• https://x.com/RHEUMarampa/status/1964138189842415720/photo/1

Optimizing outcomes of pregnancy in #lupus: 📌 all patients should undergo preconception counselling 📌 close monitoring by a multidisciplinary team - a ⬇️ cerebroplacental ratio reflects placental dysfunction #APLAR25 @RheumNow @rheumarhyme https://t.co/RSyqgpRTG5

• https://x.com/RHEUMarampa/status/1963886577081581728/photo/1
• https://x.com/RHEUMarampa/status/1963886577081581728/photo/1

@Lupusreference reviews clinical trials in LES, highlights key limitations of current outcome measures and propose a novel a clinical outcome in SLE based on « How patients feel function and survive » Very relevant to the human experience of having a chronic illness @RheumNow https://t.co/vM58C9KfQ3

• https://x.com/AurelieRheumo/status/1963879956930568311/photo/1

Controversies in ILD Join leading experts as they tackle complex topics: IPAF, MTX, SARD vs. CTD, and anti-fibrotic therapy. 📅 Sep 16, 2025 | ⏰ 7 PM ET Jeffrey Sparks, MD | Janet Pope, MD | Elena Joerns, MD Moderator: Jack Cush, MD 👉 Register: https://t.co/O4FQNyGeTr https://t.co/jIfjuWWNvp

• Welcome! You are invited to join a webinar: Controversies in ILD. After registe…

🆕 Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: https://t.co/Fn76PiGsPl Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/MalDKUjonR

• ILD: Background/Introduction (Part One) | RheumNow

AI can Dx & predict HCQ retinopathy (HR). An International, Multi-center study used retrospective data from 409 pts (171 HR+, 238 HR-) & tested on 8251 SD-OCT scans. AI Dx 100% & predicted 98.7% mean 221 D before Dx. Sensitivity 100%; specificity 98%, PPV 94%; NPV 100% https://t.co/USABVO8Ss5

Gout: Highlights from APLAR 2025 Dr. Sheila Reyes, The Philippines, reports on highlights and takeaways from lectures on the treatment of gout from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Fxd3MBUYrT https://t.co/gKjHlJXttT

• Gout: Highlights from APLAR 2025 | RheumNow

Dr. Binit Vaidya aptly poses this slide on the gout paradox: evidence-based T2T tx exist yet many still have uncontrolled dse. How can we close this gap? - address barriers to tx adherence - motivation - px education - multidisciplinary approach to px care @rheumnow #APLAR25 https://t.co/IEn9PMAxH5

• https://x.com/RHEUMarampa/status/1963867968221085944/photo/1

Colchicine for #gout patients with CV risk: - since it has a purely anti-inflammatory effect, risk of acute CV events in pts w/ high CV risk is reduced. vs. NSAIDs/steroids, colchicine remains to be a safer option for gout prophylaxis @rheumnow #APLAR25 https://t.co/WgfTcIleMd

• https://x.com/RHEUMarampa/status/1963861596645564434/photo/1
• https://x.com/RHEUMarampa/status/1963861596645564434/photo/1

SGLT2 inhibitors exert their anti-inflammatory effects by inhibiting activation of the NLRP3 inflammasome. Secondary analyses of RCTs show that SGLT2is can reduce the risk of incident #gout @RheumNow #ACR25 https://t.co/IWgyDYEQoZ

• https://x.com/RHEUMarampa/status/1963854077302899145/photo/1
• https://x.com/RHEUMarampa/status/1963854077302899145/photo/1
• https://x.com/RHEUMarampa/status/1963854077302899145/photo/1